Medtronic Posts 13.7% Organic Growth, Raises Fiscal 2027 Guidance

EarningsM&A · PartnershipCorporate Action Impact 4
โดย Insider Monkey·US·Read original
Summary · why it matters

Medtronic plc reported fiscal first-quarter 2027 revenue of nearly $9.8 billion, up 13.7% organically, while non-GAAP diluted EPS rose 15.1% to $1.45. The company raised its full-year organic revenue-growth forecast to 7.25%-7.75% from 6.75%-7.25% and lifted the lower end of its non-GAAP diluted EPS guidance to $5.94 from $5.90. Cardiovascular revenue increased 18.9% organically to $3.927 billion, with Cardiac Ablation Solutions up 88%, while Neuroscience grew 9.3% and Medical Surgical increased 10.2%. The quarter included an extra fiscal week that Medtronic estimates benefited organic growth by approximately $570 million, and non-GAAP operating margin rose only 10 basis points to 23.7%. Medtronic also committed $700 million to Cornerstone Robotics for distribution rights to its Sentire surgical system in select markets outside the United States and agreed to invest up to $80 million in Pi-Cardia, with an option to acquire the company for up to $210 million, as it proceeds with the separation of its diabetes division by the end of the year.

Impact on stocks 2

Robotics & Physical AI▲ · 2 stocks
Medtronic PLC
MDT
▲ PositiveCapitalrelevance

Medtronic posted 13.7% organic revenue growth, 15.1% EPS growth, and raised fiscal 2027 guidance

Theme Impact 3

Off-coverage companies 2

Cornerstone RoboticsPrivate▲ Positive
Demandrelevance

Medtronic committed $700 million to Cornerstone Robotics for distribution rights to its Sentire surgical system

Pi-Cardia Ltd.Private▲ Positive
Capitalrelevance

Medtronic agreed to invest up to $80 million in Pi-Cardia with an option to acquire it for up to $210 million

Related news

▲2

Intuitive Surgical Wins CE Mark for da Vinci SP in Transvaginal Gynecologic Procedures

Intuitive Surgical announced that its da Vinci SP surgical system received CE mark approval in Europe for transvaginal gynecologic procedures, the platform's first such indication globally. The authorization expands the SP system's approved applications in women's health and extends its natural orifice surgery portfolio beyond transoral and transanal procedures, supporting the company's strategy of growing the platform through new indications rather than relying solely on new system placements. The approval could help increase utilization of the existing da Vinci SP installed base across Europe, a key driver of recurring revenue through instruments, accessories and service revenue. During its second-quarter 2026 earnings call, management highlighted that SP procedures surged 61% year over year, driven by expanded indications, new instrumentation and broader adoption, while the company placed 38 SP systems in the quarter, up from 23 a year ago, taking the global installed base to 445 systems. Intuitive Surgical also noted that more than 1,000 peer-reviewed publications support the safety and efficacy of the da Vinci SP platform.
ISRG ▲
Robotics & Physical AI ▲
Zacks Investment Research·2dRead more →

Johnson & Johnson Targets Double-Digit Growth by End of Decade

Johnson & Johnson said it remains on track to grow through biosimilar competition for STELARA and expects its medicines, medical devices and pipeline to support accelerating growth through the end of the decade. Speaking at a Morgan Stanley event, Chief Executive Officer and Chairman Joaquin Duato said the company's current guidance calls for 6.5% adjusted operational sales growth and 7.3% adjusted earnings-per-share growth in 2026, with total revenue expected to exceed $100 billion for the first time. Duato said 2027 should be a better year than 2026 and that the company has line of sight to double-digit growth by the end of the decade, with more detail to come at an enterprise business review in early December. John Reed, executive vice president of Innovative Medicine and R&D, said Johnson & Johnson has 12 molecules that have achieved proof of concept and are in Phase III development, and that beyond DARZALEX it has 10 marketed medicines still early in their product life cycles. Capital allocation priorities center on launches such as ICOTYDE, INLEXZO, RYBREVANT, IMAAVY and the OTTAVA robotic surgical system, plus pipeline funding and earlier-stage business development, including the recent acquisitions of Halda Therapeutics and Firefly Bio and a collaboration with an option to acquire Sail. Duato said the company can reach double-digit growth this decade without acquisitions but views M&A as a way to reinforce growth into the following decade.
JNJ ▲
Biotech & Genomic Medicine ▲Robotics & Physical AI
MarketBeat·4dRead more →
▲

SS Innovations Launches Sri Lanka's First Robotic Cardiac Surgery Program

SS Innovations International has supported the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo using the SSi Mantra 3.0 surgical robotic system. The program began with a robotic-assisted LIMA takedown performed by SS Innovations founder and Chairman Dr. Sudhir Srivastava alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva, and Kings Hospital has completed more than 25 robotic procedures in three weeks. SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, with second-quarter revenue of $13.9 million and robotic procedures up 143% year over year to 2,528. The company's next major corporate milestone is regulatory expansion, as it pursues U.S. FDA clearance and European CE marking for the SSi Mantra system.
SSII ▲
Robotics & Physical AI ▲
NewMediaWire·7dRead more →
© 2026 MarketDXNews